Review article · 2025 · Open access
Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making
BMJ, 391, e085875 · Published 26 November 2025 · DOI 10.1136/bmj-2025-085875
In brief
“Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making” is a 2025 review article by Corentin J. Gosling and 34 co-authors, published in BMJ. OpenAlex counts 42 citations as of 17 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at BMJ.
- Citations
- 42
- Most cited in
- 2026 (42)
- Field-weighted impact
- 4.71
- References
- 40
- Authors
- 35
Abstract
OBJECTIVES: To assess the effects of and related evidence certainty of interventions for attention deficit/hyperactivity disorder (ADHD) across an individual's lifespan, and to develop a continuously updated web platform for people with lived experience of ADHD as a method to disseminate living evidence synthesis for shared decision making. DESIGN: Umbrella review and platform for shared decision making. DATA SOURCES: Six databases from inception to 19 January 2025. Study authors were contacted for additional information when necessary. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Systematic reviews that used meta-analyses of randomised controlled trials were eligible if they compared a drug or non-drug intervention with a passive control in individuals with a diagnosis of ADHD. Primary outcomes were severity of ADHD symptoms, analysed by rater type (clinician-rated, parent-rated, teacher-rated, or self-rated) and time point (short term (12 weeks, or study endpoint), medium term (26 weeks), and long term (52 weeks)),acceptability (participants dropping out for any reason), and tolerability (participants dropping out owing to any side effects). Secondary outcomes included daily functioning, quality of life, comorbid symptoms, and key side effects (decreased sleep and appetite). DATA SYNTHESIS: Eligible meta-analyses were re-estimated with a standardised statistical approach. Methodological quality was assessed using AMSTAR-2. Evidence certainty was evaluated using an algorithmic version of the GRADE framework, adapted for drug and non-drug interventions. RESULTS: 115 of 414 full text articles were deemed eligible and 299 were excluded; the eligible articles comprised 221 unique combinations of participants, interventions, comparators, and outcomes. For each combination, the most recent and methodologically robust meta-analysis was selected for re-estimation, which gave 221 re-estimated meta-analyses in total, derived from 47 meta-analytic reports. In the short term, alpha-2 agonists, amphetamines, atomoxetine, methylphenidate, and viloxazine showed medium to large effect sizes in reducing the severity of ADHD symptoms in children and adolescents, with moderate to high certainty evidence. Methylphenidate showed consistent benefits across raters (standardised mean difference >0.75, 95% confidence interval (CI) 0.56 to 1.03; moderate or high certainty evidence). These interventions showed lower tolerability than the placebo, but this effect was not significant for methylphenidate and atomoxetine. In adults, atomoxetine, cognitive behavioural therapy, methylphenidate (and, when restricting analyses to high quality trials, amphetamines) showed at least moderate certainty evidence of efficacy on ADHD symptoms, with medium effect sizes. Methylphenidate, amphetamines, and atomoxetine had worse tolerability than placebo (methylphenidate, risk ratio 0.50, 95% CI 0.36 to 0.69; amphetamines, 0.40, 0.22 to 0.72; atomoxetine, 0.45, 0.35 to 0.58). Some non-drug interventions (acupuncture and cognitive behavioural therapy in children and adolescents, and mindfulness in adults) showed large effect…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Gosling, C. J., Garcia‐Argibay, M., De Prisco, M., Arrondo, G., Ayrolles, A., Antoun, S., Caparos, S., Catalán, A., Ellul, P., Dobrosavljevic, M., Farhat, L. C., Fico, G., Eudave, L., Groenman, A. P., Højlund, M., Jurek, L., Nourredine, M., Oliva, V., Parlatini, V., . . . Cortese, S. (2025). Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making. BMJ, 391, e085875. https://doi.org/10.1136/bmj-2025-085875
MLA 9
Gosling, Corentin J., et al. “Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making.” BMJ, vol. 391, 2025, p. e085875. https://doi.org/10.1136/bmj-2025-085875.
Chicago
Gosling, Corentin J., Miguel Garcia‐Argibay, Michele De Prisco, Gonzalo Arrondo, Anaël Ayrolles, Stéphanie Antoun, Serge Caparos, et al. 2025. “Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making.” BMJ 391: e085875. https://doi.org/10.1136/bmj-2025-085875.
Harvard
Gosling, C. J. et al. (2025) ‘Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making’, BMJ, 391, p. e085875. doi:10.1136/bmj-2025-085875.
IEEE
C. J. Gosling et al., “Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making,” BMJ, vol. 391, p. e085875, 2025, doi: 10.1136/bmj-2025-085875.
BibTeX
@article{gosling2025benefits,
title = {{Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making}},
author = {Gosling, Corentin J. and Garcia‐Argibay, Miguel and De Prisco, Michele and Arrondo, Gonzalo and Ayrolles, Anaël and Antoun, Stéphanie and Caparos, Serge and Catalán, Ana and Ellul, Pierre and Dobrosavljevic, Maja and Farhat, Luís C. and Fico, Giovanna and Eudave, Luis and Groenman, Annabeth P. and Højlund, Mikkel and Jurek, Lucie and Nourredine, Mikaïl and Oliva, Vincenzo and Parlatini, Valeria and Psyllou, Constantina and de Pablo, Gonzalo Salazar and Tomlinson, Anneka and Westwood, Samuel James and Cipriani, Andrea and Correll, Christoph Ulrich and Yon, Dong Keon and Larsson, Henrik and Ostinelli, Edoardo Giuseppe and Shin, Jae Il and Fusar‐Poli, Paolo and others},
journal = {BMJ},
year = {2025},
volume = {391},
pages = {e085875},
doi = {10.1136/bmj-2025-085875},
url = {https://doi.org/10.1136/bmj-2025-085875}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- attention deficit hyperactivity disorder
- ADHD intervention
- methylphenidate
- atomoxetine
- alpha-2 adrenergic agonists
- amphetamine
- viloxazine
- stimulant side effects
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Gosling, C. J., Garcia‐Argibay, M., De Prisco, M., Arrondo, G., Ayrolles, A., Antoun, S., Caparos, S., Catalán, A., Ellul, P., Dobrosavljevic, M., Farhat, L. C., Fico, G., Eudave, L., Groenman, A. P., Højlund, M., Jurek, L., Nourredine, M., Oliva, V., Parlatini, V., . . . Cortese, S. (2025). Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making. BMJ, 391, e085875. https://doi.org/10.1136/bmj-2025-085875
How many times has this paper been cited?
42 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at BMJ: sign in and open the PDF from this page.
Who wrote this paper?
Corentin J. Gosling, Miguel Garcia‐Argibay, Michele De Prisco, Gonzalo Arrondo, Anaël Ayrolles, Stéphanie Antoun, Serge Caparos, Ana Catalán, Pierre Ellul, Maja Dobrosavljevic, Luís C. Farhat, Giovanna Fico and 23 more.
What is the DOI of this paper?
10.1136/bmj-2025-085875, permanently at https://doi.org/10.1136/bmj-2025-085875. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.